alemtuzumab versus interferon beta 1a for relapsing‐remitting multiple sclerosis

BACKGROUND: Alemtuzumab is a humanised monoclonal antibody that alters the circulating lymphocyte pool, causing prolonged lymphopenia, thus remoulding the immune repertoire that accompanies homeostatic lymphocyte reconstitution. It has been proved more effective than interferon (IFN) 1a for the trea...

Full description

Saved in:
Bibliographic Details
Published in:Cochrane Database Syst Rev
Main Authors: Zhang, Jian, Shi, Shengliang, Zhang, Yueling, Luo, Jiefeng, Xiao, Yousheng, Meng, Lian, Yang, Xiaobo
Format: Artigo
Language:Inglês
Published: John Wiley & Sons, Ltd 2017
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6486233/
https://ncbi.nlm.nih.gov/pubmed/29178444
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD010968.pub2
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items